Head-to-head · WeighScore
Contour Health vs Omada Health
The verdict
Contour Health takes it — 66.8/100 to 55.6/100.
Contour Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Contour Health (Desert Contour LLC) is a Utah-based telehealth provider offering compounded semaglutide and tirzepatide through a named 503A pharmacy partner, Strive Pharmacy.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Contour Health | Omada Health |
|---|---|---|
| WeighScore | 66.8/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #177 | #435 |
| Semaglutide | $160/mo (starting dose, compounded) | Not disclosed |
| Tirzepatide | $300/mo (starting dose, compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #177 · C
Strengths
- Free medical consultation — no charge to talk with a provider before starting
- Pay-per-vial pricing with no long-term subscription commitment required to participate
- Names its compounding pharmacy partner (Strive Pharmacy, 503A accredited) — a real transparency signal
- LegitScript badge links to a genuine, working LegitScript verification checker for the domain
- Board-certified Medical Director and named nurse-practitioner care team, not anonymous providers
Where it loses points
- State availability list is not published — Terms of Service only says "certain states"
- All product purchases are non-refundable per Terms of Service
- Compounded injectable only — no oral option, no brand-name Wegovy/Zepbound/Ozempic/Mounjaro
- Terms of Service also describe an optional subscription tier with a 3-month minimum, despite marketing emphasizing "no subscriptions"
- No insurance, Medicare, or Medicaid accepted — cash-pay or HSA/FSA only
Graded #435 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.